Close

Acadia Pharma (ACAD) Commences Pimavanserin Phase 2 in MDD

Go back to Acadia Pharma (ACAD) Commences Pimavanserin Phase 2 in MDD

ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder

December 1, 2016 9:00 AM EST

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of CLARITY, a Phase II study to evaluate pimavanserin for adjunctive treatment in patients with major depressive disorder (MDD) who have an inadequate response to first-line therapies for clinical depression. Pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that may play a role in depression.

Major depressive disorder affects millions of people in the United... More